Henry Q. Xiong, Gauri R. Varadhachary, Joan C. Blais, Kenneth R. Hess, James L. Abbruzzese and Robert A. Wolff Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer Cancer 113
Version of Record online: 28 AUG 2008 | DOI: 10.1002/cncr.23810
The combination of capecitabine and oxaliplatin (XELOX) was studied in 39 evaluable patients with gemcitabine-pretreated, advanced pancreatic cancer. This combination is active and well-tolerated as a second-line regimen in patients with a good performance status.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field